Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Amantadine; Interferon; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms VKF3
- 28 Aug 2010 Status changed from completed to active, no longer recruiting as reported by Netherlands Trial Register.
- 28 Aug 2009 Additional trial identifier NTR560 identified as reported by ISRCTN: Current Controlled Trials.
- 18 Aug 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.